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Journal of Global Antimicrobial Resistance 24 (2021) 178–179Letter to the Editor
Hydroxychloroquine serum concentrations in
non-critical care patients infected with
SARS-CoV-2
Sir,
Hydroxychloroquine (HCQ) has been widely used to treat
infection with SARS-CoV-2 (severe acute respiratory syndrome
coronavirus 2) but most recently has been shown to be of no
benefit in a large randomised clinical trial [1]. Detailed
information on the pharmacodynamics of HCQ is lacking,
but measures of the in vitro activity of HCQ against SARS-CoV-
2 are available as well as pharmacokinetic data derived
from analysis of patients with conditions other than SARS-
CoV-2 infection who received HCQ. HCQ is much less
active against SARS-CoV-2 in vitro than it is against Plasmodi-
um spp. Pharmacokinetic data from patients with SARS-CoV-2 are
sparse and are absent for those outside of critical care [2]. Here we
report data on the serum concentrations of HCQ in patients who
were recruited into the Randomised Evaluation of COVID-19
Therapy (RECOVERY) trial. Permission to take and use stored
serum was ethically approved as part of the Diagnostic and
Severity markers in COVID-19 to Enable Rapid triage (DISCOVER)
study. Patients received HCQ at a dose of 800 mg 6 h apart, then
400 mg every 6 h later followed by 400 mg every 12 h
subsequently.
HCQ was assayed using a recently developed liquid
chromatography–tandem mass spectrometry (LCMS/MS) method.
Serum was deproteinised with acetonitrile after addition of the
internal standard (chloroquine). The method was validated over a
working range of 0.005–1 mg/L. There was no evidence of drug loss
in gel separator tubes compared with plain tubes or after 24 h at
room temperature. The mean blood/plasma partitioning ratio was
1.64  0.25.
Seven patients were recruited into the HCQ treatment arm.
Subsequently one patient (male, aged 58 years) had no blood
samples drawn and a second patient (male, aged 84 years) only
received a single dose of 800 mg. Of the five remaining
patients, two were male and three were female with a mean
 standard deviation (range) age of 57.4  20.7 years (26–83
years) and weight of 70.6  4.2 kg (65.4–75.0 kg). All patients
had an estimated glomerular filtration rate (eGFR) >80 mL/min
on Day 0, and none had serum bilirubin, alkaline phosphatase
or alanine aminotransferase enzyme levels more than three
times the normal level. Three of the five patients had co-
morbidities, namely cardiac, neurological or neoplastic dis-
ease. All HCQ serum concentrations were 0.005 mg/L either
Concentrations on Days 1, 2, 3 and 4 were 0.4  0.35 mg/L
(n = 3), 0.43  0.14 mg/L (n = 3), 0.46 mg/L (n = 2) and 0.62 mg/L
(n = 2), respectively.
The timing of sampling after oral dosing was variable, being
2.9  3.5 h (0.12–8.5 h), although three-quarters were taken within
4 h of the dose being administered.
Data on the pharmacokinetics of HCQ have been accumulated in
patients with conditions other than SARS-CoV-2 infection. The
European summary of product characteristics (SmPC) suggests
that after a single 400 mg dose, the peak serum concentration was
0.105 mg/L at 1.8 h post-dose [3]. Pharmacokinetic and modelling
data exist for SARS-CoV2-infected patients. Yoa et al. simulated
several potential doses of HCQ, suggesting that in Chinese subjects
(usually smaller and lighter than European or North American
patients) that a dose of 400 mg twice daily and 200 mg twice daily
may be optimal [4]. Interestingly, mean serum HCQ concentrations
were not predicted to be >1 mg/L until 4–5 days of therapy with
this regimen [4]. Downes et al. simulated doses more akin to those
used in the RECOVERY trial, i.e. 1600 mg on Day 1 and 400 mg/day
thereafter [5]. The predicted maximum concentration (Cmax)
(interquartile range) was 2.7 mg/L (2.2–3.3 mg/L) and area under
the concentration–time curve (AUC) was 109.9 mg/L h. Perinel
et al. performed a study of HCQ serum concentrations in French
patients in critical care receiving 200 mg three times daily; most
were mechanically ventilated [2]. It took 2–7 days for serum
concentrations to reach 1 mg/L. They also suggested a reference
range of >1 mg/L and <2 mg/L but only 8 of 13 patients reached
these concentrations [2]. HCQ dosing in the RECOVERY trial is
higher than those in these studies and, despite this, all of our
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journal home page : www.elsevier .com/ loca te / jgarFig. 1. Serum concentrations of hydroxychloroquine.before or on the first day of dosing. Serum concentrations on
subsequent days after starting treatment are shown in Fig. 1.http://dx.doi.org/10.1016/j.jgar.2020.12.018
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oncentration of <1 mg/L, which is a concentration well below the
eported EC50 values for HCQ against SARS-CoV-2 in vitro [6]. It
ay be expected that patients not receiving critical care may have
etter absorption than those in the intensive care unit.
There are a number of limitations of our study, most obviously
he small number of patients and samples available. However, our
ata indicate that HCQ concentrations are lower than might be
xpected, even with a high-dose regimen.
Given that HCQ is likely to have marginal pharmacodynamics in
ARS-CoV-2 infection, these data may in part help explain the lack
f benefit in randomised clinical trials and also further question its
otential use in prophylaxis.
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